HRP931515B1 - Combination of a cholesterol biosynthesis inhibitor and a beta-lactam cholesterol absorbtion inhibitor - Google Patents

Combination of a cholesterol biosynthesis inhibitor and a beta-lactam cholesterol absorbtion inhibitor

Info

Publication number
HRP931515B1
HRP931515B1 HR07/995,488A HRP931515A HRP931515B1 HR P931515 B1 HRP931515 B1 HR P931515B1 HR P931515 A HRP931515 A HR P931515A HR P931515 B1 HRP931515 B1 HR P931515B1
Authority
HR
Croatia
Prior art keywords
inhibitor
cholesterol
pct
beta
combination
Prior art date
Application number
HR07/995,488A
Other languages
English (en)
Inventor
Harry R Davis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HRP931515A2 publication Critical patent/HRP931515A2/xx
Publication of HRP931515B1 publication Critical patent/HRP931515B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR07/995,488A 1992-12-23 1993-12-22 Combination of a cholesterol biosynthesis inhibitor and a beta-lactam cholesterol absorbtion inhibitor HRP931515B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99548892A 1992-12-23 1992-12-23

Publications (2)

Publication Number Publication Date
HRP931515A2 HRP931515A2 (en) 1996-12-31
HRP931515B1 true HRP931515B1 (en) 2000-02-29

Family

ID=25541876

Family Applications (1)

Application Number Title Priority Date Filing Date
HR07/995,488A HRP931515B1 (en) 1992-12-23 1993-12-22 Combination of a cholesterol biosynthesis inhibitor and a beta-lactam cholesterol absorbtion inhibitor

Country Status (32)

Country Link
US (1) US5661145A (lv)
EP (1) EP0675714B1 (lv)
JP (1) JP3992728B2 (lv)
KR (1) KR100306936B1 (lv)
CN (1) CN1090479C (lv)
AT (1) ATE175872T1 (lv)
AU (1) AU680864B2 (lv)
CA (1) CA2152351C (lv)
CZ (1) CZ287125B6 (lv)
DE (1) DE69323213T2 (lv)
DK (1) DK0675714T3 (lv)
EE (1) EE03383B1 (lv)
ES (1) ES2128552T3 (lv)
FI (1) FI952916A0 (lv)
GR (1) GR3029405T3 (lv)
HR (1) HRP931515B1 (lv)
HU (1) HU221724B1 (lv)
IL (1) IL108112A (lv)
LT (1) LT3300B (lv)
LV (1) LV10919B (lv)
MX (1) MX9308053A (lv)
MY (1) MY109538A (lv)
NO (1) NO311325B1 (lv)
NZ (1) NZ259790A (lv)
PL (1) PL174128B1 (lv)
SG (1) SG45147A1 (lv)
SI (1) SI9300677A (lv)
SK (1) SK281173B6 (lv)
TW (1) TW319698B (lv)
WO (1) WO1994014433A1 (lv)
YU (1) YU49060B (lv)
ZA (1) ZA939552B (lv)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
JPH09511753A (ja) * 1994-09-20 1997-11-25 ファイザー・インコーポレーテッド コレステロール吸収阻害薬とコレステロール合成阻害薬の併用
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
EA000514B1 (ru) 1995-11-02 1999-10-28 Варнер-Ламберт Компани Способ нормализации липопротеидного профиля плазмы крови у млекопитающего и фармацевтическая композиция для его осуществления
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
AU4343500A (en) * 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
JP4945876B2 (ja) * 2000-04-05 2012-06-06 東レ株式会社 ハイモビリティーグループタンパクの吸着材および体液浄化カラム
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
CN101297969B (zh) * 2001-01-26 2011-03-09 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
CA2442219C (en) 2001-03-28 2007-09-11 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
AU2002336609B2 (en) * 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
CN101785772A (zh) * 2001-09-21 2010-07-28 先灵公司 使用甾醇吸收抑制剂治疗或预防脉管炎的方法
WO2003043624A1 (en) 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2003291227A1 (en) 2002-11-05 2004-06-07 Smithkline Beecham Corporation Antibacterial agents
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CN1756755A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
EP1810971B1 (en) * 2003-03-07 2013-12-25 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7235543B2 (en) * 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20050113314A1 (en) * 2003-08-29 2005-05-26 Fong Benson M. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
AU2004303742B2 (en) 2003-12-23 2008-06-19 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
EP1723414A4 (en) * 2004-01-16 2008-03-26 Merck & Co Inc NPC1L1 (NPC3) AND METHOD FOR IDENTIFYING ITS LIGANDS
RU2408591C9 (ru) * 2004-07-01 2011-04-27 Шеринг Корпорейшн Производные пиперидина, фармацевтическая композиция на их основе и их применение
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
WO2006039334A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076569A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
EP1846410B1 (en) 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
CN101243072A (zh) * 2005-06-20 2008-08-13 先灵公司 用作组胺h3拮抗剂的哌啶衍生物
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057072A1 (es) * 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
JP2009521452A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション コレステロール降下剤およびｈ３受容体アンタゴニスト／逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007100807A2 (en) 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
AR060623A1 (es) * 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
JP2010514841A (ja) * 2007-01-03 2010-05-06 グレン ブイ． コルネット， 肺疾患および心疾患の処置におけるシクレタニンおよびｐｋｃ阻害剤
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
MX2011009852A (es) 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
US9586900B2 (en) 2012-09-05 2017-03-07 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014039412A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
SG11202100417RA (en) 2018-07-19 2021-02-25 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2023014197A (es) 2021-06-16 2024-01-18 Celgene Corp Compuestos de azetidinilo que comprenden un grupo de acido carboxilico para el tratamiento de enfermedades neurodegenerativas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5085473A (en) * 1990-10-09 1992-02-04 Yuhe Yang Air actuated car curtain device
MY131273A (en) 1991-07-23 2007-07-31 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
ES2613245T3 (es) 2012-01-26 2017-05-23 Intralot S.A. - Integrated Lottery Systems And Services Métodos y sistemas para dispensar

Also Published As

Publication number Publication date
LV10919A (lv) 1995-12-20
YU49060B (sh) 2003-08-29
CN1090479C (zh) 2002-09-11
CA2152351C (en) 2009-09-22
HU9501854D0 (en) 1995-08-28
SI9300677A (en) 1994-09-30
IL108112A0 (en) 1994-04-12
IL108112A (en) 1999-11-30
EP0675714B1 (en) 1999-01-20
MX9308053A (es) 1994-06-30
FI952916A (fi) 1995-06-14
PL309636A1 (en) 1995-10-30
SK78395A3 (en) 1996-05-08
NZ259790A (en) 1997-02-24
EE9400341A (et) 1996-04-15
LT3300B (en) 1995-06-26
ATE175872T1 (de) 1999-02-15
US5661145A (en) 1997-08-26
TW319698B (lv) 1997-11-11
DE69323213D1 (de) 1999-03-04
HU221724B1 (hu) 2002-12-28
LV10919B (en) 1996-04-20
GR3029405T3 (en) 1999-05-28
AU5872094A (en) 1994-07-19
DE69323213T2 (de) 1999-07-08
NO311325B1 (no) 2001-11-19
PL174128B1 (pl) 1998-06-30
AU680864B2 (en) 1997-08-14
JPH08505141A (ja) 1996-06-04
DK0675714T3 (da) 1999-09-13
ZA939552B (en) 1994-10-12
CZ164395A3 (en) 1996-03-13
HRP931515A2 (en) 1996-12-31
ES2128552T3 (es) 1999-05-16
FI952916A0 (fi) 1995-06-14
JP3992728B2 (ja) 2007-10-17
YU80293A (sh) 1997-12-05
NO952529L (no) 1995-06-23
SG45147A1 (en) 1998-01-16
WO1994014433A1 (en) 1994-07-07
KR100306936B1 (ko) 2001-11-30
CZ287125B6 (en) 2000-09-13
SK281173B6 (sk) 2000-12-11
CA2152351A1 (en) 1994-07-07
CN1095591A (zh) 1994-11-30
NO952529D0 (no) 1995-06-23
MY109538A (en) 1997-02-28
HUT72081A (en) 1996-03-28
EP0675714A1 (en) 1995-10-11
LTIP1514A (en) 1994-10-25
EE03383B1 (et) 2001-04-16

Similar Documents

Publication Publication Date Title
LTIP1514A (en) Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
GEP20033006B (en) Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
AU6969994A (en) A pharmaceutical composition for the intranasal administration of hydroxocobalamin
BG97678A (en) Beta -carotene and/or vitamin e therapy for inhibition of major vascular events
AU3451797A (en) Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
EP0646007A4 (lv)
AU4923093A (en) Inhibitors of metazoan parasite proteases
IL111917A0 (en) A pharmaceutical composition containing a parasympathomimetic compound and a parasympatholytic compound
WO2000038620A3 (en) A composition useful to treat periodontal disease
AU2961199A (en) Hiv cofactor inhibitors and medicinal compositions for preventing or treating hiv-infection
GR3036241T3 (en) METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17-g(b)-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5-g(a)-ANDROST-1-EN-3-ONES.
AU7941294A (en) Composition for the treatment or prevention of herpes
AU7460894A (en) Use of 4'-iodo-4'-deoxydoxorubicin for the treatment of amyloidosis
AU3347193A (en) Fungicidal compositions
DE69717277D1 (en) Imidazopyridine
AU5625194A (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
UA41376C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ АНДРОГЕННОЇ АЛОПЕЦІЇ ІНГІБІТОРАМИ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
CA2135712A1 (en) The synergistic activity of glutaraldehyde in the presence of oxidants

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20101202

Year of fee payment: 18

PBON Lapse due to non-payment of renewal fee

Effective date: 20111223